| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/23/2003 | WO2003006680A2 Omi and domains thereof that disrupt iap-caspase interaction |
| 01/23/2003 | WO2003006668A2 Haptoglobin Derived Antioxidants |
| 01/23/2003 | WO2003006661A2 Transgenic plants expressing cobalamin binding proteins |
| 01/23/2003 | WO2003006657A2 Gene-regulatory elements for gene therapy, for the prevention and diagnosis of metastases and for the gene therapy of tumours |
| 01/23/2003 | WO2003006654A2 Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom |
| 01/23/2003 | WO2003006646A1 Regulation of human aminopeptidase n |
| 01/23/2003 | WO2003006642A1 Mediating the effects of alcohol consumption by orally administering active dry yeast |
| 01/23/2003 | WO2003006641A2 Epsti1, a gene induced by epithelial-stromal interaction in human breast cancer |
| 01/23/2003 | WO2003006621A2 Super osteocalcin promoter for the treatment of calcified tumors and tissues |
| 01/23/2003 | WO2003006620A2 Linear and cyclic melanocortin receptor-specific peptides |
| 01/23/2003 | WO2003006619A2 Calcineurin modulators |
| 01/23/2003 | WO2003006611A2 GPCs AS MODIFIERS OF THE IRRTK AND p21 PATHWAYS AND METHODS OF USE |
| 01/23/2003 | WO2003006609A2 Human cytokine receptor |
| 01/23/2003 | WO2003006604A2 Cyclic peptides as potent and selective melanocortin-4 receptor agonists |
| 01/23/2003 | WO2003006603A2 Triple polypeptide complexes |
| 01/23/2003 | WO2003006531A1 Keratin-based products and methods for their productions |
| 01/23/2003 | WO2003006501A2 G-csf conjugates |
| 01/23/2003 | WO2003006500A1 Method for obtaining a tgf-beta enriched protein fraction in activated form, protein fraction and therapeutic applications |
| 01/23/2003 | WO2003006496A2 Protein variants of neocarzinostatine and its homologues and their use |
| 01/23/2003 | WO2003006492A2 Biologically active peptides |
| 01/23/2003 | WO2003006491A2 Peptide-based compounds for targeting intergin receptors |
| 01/23/2003 | WO2003006490A1 Bridged bicyclic serine protease inhibitors |
| 01/23/2003 | WO2003006489A2 Prodrugs of excitatory amino acids |
| 01/23/2003 | WO2003006483A2 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| 01/23/2003 | WO2003006481A2 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| 01/23/2003 | WO2003006479A1 Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death |
| 01/23/2003 | WO2003006478A1 Oligonucleotide-containing pharmacological compositions and their use |
| 01/23/2003 | WO2003006444A2 Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity |
| 01/23/2003 | WO2003006104A2 Lymphatic endothelial cells materials and methods |
| 01/23/2003 | WO2003006070A2 Improved chelator conjugates |
| 01/23/2003 | WO2003006067A2 Composition comprising a parvovirus vp1-variant and a parvovirus ns1 protein for induction of cytolysis |
| 01/23/2003 | WO2003006058A1 Cd25+ differential markers and uses thereof |
| 01/23/2003 | WO2003006057A1 Composition and method for the treatment of disease |
| 01/23/2003 | WO2003006056A2 End-locked five-helix protein |
| 01/23/2003 | WO2003006054A1 Pharmaceutically stable hemostatic compositions |
| 01/23/2003 | WO2003006053A1 HUMAN INTERFERON-β FORMULATIONS |
| 01/23/2003 | WO2003006051A1 Use of corticotroph-derived glycoprotein hormone to induce lipolysis |
| 01/23/2003 | WO2003006050A1 Preventives/remedies for brain edema |
| 01/23/2003 | WO2003006049A1 Gonadotropin releasing hormone antagonists in gel-forming concentrations |
| 01/23/2003 | WO2003006048A1 Combination of chips (chemotaxis inhibiting protein from staphylococcus aureus)-based compounds |
| 01/23/2003 | WO2003006047A2 Methods for reducing immunogenicity of polypeptides |
| 01/23/2003 | WO2003006046A1 Use of antimicrobial peptides as preservatives in ophthalmic preparations including solutions emulsions and suspensions |
| 01/23/2003 | WO2003006044A1 Methods and compositions for controlling protein assembly or aggregation |
| 01/23/2003 | WO2003006043A1 Surfactant peptide nanostructures, and uses thereof |
| 01/23/2003 | WO2003006042A1 Peptide for regulation of tissue plasminogen activator |
| 01/23/2003 | WO2003006041A1 Preventives/remedies for malignant tumor |
| 01/23/2003 | WO2003005964A2 Recombinant vsv for the treatment of tumor cells |
| 01/23/2003 | WO2003005961A2 A controlled release biodegradable gel matrix |
| 01/23/2003 | WO2003005956A2 A hydroxamic acid thrombospondin peptide analog that inhibits aggrecanase activity |
| 01/23/2003 | WO2003005953A2 Viral proteins capable of binding lar |
| 01/23/2003 | WO2003005941A2 Insert for the treatment of dry eye |
| 01/23/2003 | WO2003005888A2 Lipophilin complexes for use in cancer diagnosis and therapy |
| 01/23/2003 | WO2003005838A1 Food composition offering stress relaxation to mammals |
| 01/23/2003 | WO2003005837A1 Enteral formulations |
| 01/23/2003 | WO2003005819A1 Use of cross-linked, covalently bound urokinase plasminogen activator (scupa)-urokinase plasminogen activator receptor (supar) complex as a fibrinolytic agent |
| 01/23/2003 | WO2003005812A2 Modulation of metabolism of steroids and xenobiotics |
| 01/23/2003 | WO2002098908A9 Osteoclastogenesis inhibitory factor, sequence coding for it and uses |
| 01/23/2003 | WO2002090578A9 Methods and means of histone methylation |
| 01/23/2003 | WO2002086058A3 Method for producing catalytic antibodies (variants), antigens for immunisation and nucleotide sequence |
| 01/23/2003 | WO2002083726A3 A novel zinc finger protein and uses thereof |
| 01/23/2003 | WO2002080842A3 Medicament and method for diagnosing an autoimmune condition_in particular psoriasis |
| 01/23/2003 | WO2002072827A9 Traf3-binding b cell-specific receptor |
| 01/23/2003 | WO2002072005A3 Linear y-carboxyglutamate rich conotoxins |
| 01/23/2003 | WO2002070676A3 Use of protein histidine phosphatase |
| 01/23/2003 | WO2002070002A9 Methods for regulation of immune responses to conditions involving mediator-induced pathology |
| 01/23/2003 | WO2002064740A9 Cone snail peptides |
| 01/23/2003 | WO2002060468A3 Antiviral activities of primate theta defensins and mammalian cathelicidins |
| 01/23/2003 | WO2002060436A3 Use of fredericamycin a and its derivatives in the treatment of pin1-associated states |
| 01/23/2003 | WO2002055152A9 Composition for inducing islet neogenesis, containing gastrin/cck receptor ligands and egf receptor ligands |
| 01/23/2003 | WO2002054940A9 Bone morphogenetic protein-2 in the treatment and diagnosis of cancer |
| 01/23/2003 | WO2002053711A3 Use of transcription factor yb-1 in adenoviral systems |
| 01/23/2003 | WO2002052030A3 Compositions and methods enabling a totally internally controlled amplification reaction |
| 01/23/2003 | WO2002050254A3 Crystal structure of glycogen synthase kinase 3 beta |
| 01/23/2003 | WO2002049617A3 Self forming, thermodynamically stable liposomes and their applications |
| 01/23/2003 | WO2002048388A9 Method of inhibiting infection by hcv, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood preventing viral entry into a cell |
| 01/23/2003 | WO2002046364A9 Genes associated with mechanical stress, expression products therefrom, and uses thereof |
| 01/23/2003 | WO2002045773A3 Use of electrolytes (ions in solution) to suppress charging of inhalation aerosols |
| 01/23/2003 | WO2002042435A3 Regulation of human tyrosine phosphatase |
| 01/23/2003 | WO2002040498A3 Reduction of antioxidant enzyme levels in tumor cells using antisense oligonucleotides |
| 01/23/2003 | WO2002036767A3 Therapeutic oligonucleotides of reduced toxicity |
| 01/23/2003 | WO2002036741A3 Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme |
| 01/23/2003 | WO2002033095A3 Regulation of human serine-threonine protein kinase |
| 01/23/2003 | WO2002031162A3 Regulation of human phospholipase a2-like enzyme |
| 01/23/2003 | WO2002029059A3 Nogo receptor homologs |
| 01/23/2003 | WO2002026999A3 Regulation of human adam-ts-like protein |
| 01/23/2003 | WO2002026775A3 Compositions and methods for regulating apoptosis |
| 01/23/2003 | WO2002024739A3 Spas-1 cancer antigen |
| 01/23/2003 | WO2002024732A3 Methods for improving the antagonistic/agonistic properties of peptidic antagonists/agonists of the corticotropin-releasing factor receptor (crfr) |
| 01/23/2003 | WO2002022659A3 DISCRIMINATION BETWEEN GnRH-I AND GnRH-II |
| 01/23/2003 | WO2002022152A3 Use of deltorphin a and/or dermorphin h for protection against ischemia and reperfusion injury |
| 01/23/2003 | WO2002020619A3 HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3) |
| 01/23/2003 | WO2002020569A3 Mammalian genes; related reagents and methods |
| 01/23/2003 | WO2002019981A3 Cosmetic and pharmaceutical composition comprising chelating/sequestering agents and their cosmetic and dermatological use |
| 01/23/2003 | WO2002018585A3 Packaging of positive-strand rna virus replicon particles |
| 01/23/2003 | WO2002018574A3 Human interleukin-four induced protein |
| 01/23/2003 | WO2002017893A3 Sgk2 and sgk3 used as diagnostic and therapeutic targets |
| 01/23/2003 | WO2002016598A3 Nucleic acid and corresponding protein named 158p1h4 useful in the treatment and detection of bladder and other cancers |
| 01/23/2003 | WO2002016553A3 Regulator gene and system useful for the diagnosis and therapy of osteoporosis |
| 01/23/2003 | WO2002015661A3 Inhibitors of hiv replication and method of treatment of hiv infections |
| 01/23/2003 | WO2002014364A3 Rattlesnake venom gland proteins |